The following article is intended strictly for educational and research reference purposes. All compounds discussed are for laboratory research use only and are not intended for human or animal consumption.
Introduction: The Melanocortin Receptor Family and Synthetic Peptide Ligands
The melanocortin receptor (MCR) system comprises five G protein-coupled receptor subtypes—MC1R through MC5R—each encoded by distinct genes and expressed across divergent tissue compartments. These receptors are activated by endogenous peptides derived from proopiomelanocortin (POMC), including α-melanocyte-stimulating hormone (α-MSH), β-MSH, γ-MSH, and adrenocorticotropic hormone (ACTH). Despite sharing a conserved His-Phe-Arg-Trp pharmacophore essential for receptor activation, the five subtypes mediate remarkably different physiological processes: MC1R governs melanogenesis in melanocytes, MC2R mediates adrenal steroidogenesis, MC3R and MC4R regulate energy homeostasis and neuroendocrine signaling in the central nervous system, and MC5R modulates exocrine gland function and lipid metabolism in skeletal muscle and adipose tissue (Yang, 2011; Ji et al., 2022).
The relatively low sequence homology (40–60%) among the five receptor subtypes has made the development of subtype-selective ligands a persistent challenge in melanocortin pharmacology. Three synthetic α-MSH analogs—Melanotan I (MT-I, also known as afamelanotide), Melanotan II (MT-II), and PT-141 (bremelanotide)—represent three distinct structural approaches to engaging this receptor family. Their divergent selectivity profiles offer valuable pharmacological tools for dissecting melanocortin signaling in cell-based and in vivo research models.
Receptor Subtype Distribution and Signaling Architecture
All five melanocortin receptors couple primarily to the stimulatory G protein Gs, activating adenylyl cyclase and elevating intracellular cyclic adenosine monophosphate (cAMP). However, recent structural and pharmacological studies have revealed significant complexity beyond this canonical pathway. MC4R, for example, can additionally signal through Gq/11α, and loss of this secondary signaling pathway—even with intact Gs/cAMP coupling—has been shown to produce hyperphagia and obesity in murine models (Sridhar & Gumpeny, 2024).
Landmark cryo-electron microscopy (cryo-EM) studies have now resolved the structures of all five melanocortin receptors. In 2021, Israeli et al. published the first cryo-EM structure of the MC4R–Gs signaling complex bound to setmelanotide at 2.9 Å resolution, revealing a calcium-dependent molecular switch critical for agonist efficacy (Israeli et al., 2021). In 2023, Feng et al. resolved the structures of γ-MSH-bound MC3R–Gs and α-MSH-bound MC5R–Gs complexes, demonstrating that the melanocortin pharmacophore adopts a characteristic “U-shape” conformation within a wide-open orthosteric pocket (Feng et al., 2023). Most recently, Feng et al. (2025) determined unliganded cryo-EM structures of all five MCR–Gs complexes at resolutions between 2.75 and 3.12 Å, providing the structural basis for the constitutive activity that distinguishes this receptor family from most other GPCRs.
These structural advances are complemented by the identification of MC4R-specific orthosteric nanobody agonists that achieve selective receptor activation through binding modalities distinct from peptide ligands (Fontaine et al., 2024).
All compounds referenced herein are intended solely for in vitro and preclinical research applications. These materials are not approved for human or animal use.
Melanotan I: A Linear α-MSH Analog with MC1R Preference
Melanotan I (afamelanotide; [Nle4,D-Phe7]α-MSH) is a 13-amino-acid linear peptide differing from endogenous α-MSH by only two residues: norleucine replaces methionine at position 4, preventing oxidative degradation, and D-phenylalanine replaces L-phenylalanine at position 7, conferring enhanced receptor binding affinity and enzymatic resistance (Mun et al., 2023). The resulting compound, also designated NDP-MSH or NDP-α-MSH, demonstrates dramatically improved binding parameters across all non-MC2R subtypes compared to native α-MSH.
Competitive binding assays have established Ki values for NDP-MSH of approximately 0.085 nM at MC1R, 0.4 nM at MC3R, 3.8 nM at MC4R, and 5.1 nM at MC5R—representing 3- to 1,400-fold improvements over the parent α-MSH peptide at various subtypes. While MT-I retains measurable activity at MC3R, MC4R, and MC5R, its highest affinity is at MC1R, where it functions as a potent full agonist stimulating eumelanin biosynthesis through the tyrosinase pathway. The MC1R selectivity ratio (MC1R vs. MC4R) of approximately 45-fold provides meaningful, though not absolute, preferential engagement of the pigmentation pathway (Mun et al., 2023; Böhm et al., 2025).
Melanotan II: A Cyclic Non-Selective Pan-MCR Agonist
Melanotan II (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) represents a fundamentally different structural approach. Cyclization of the core pharmacophore through a lactam bridge between Asp5 and Lys10 constrains the peptide backbone, reducing the 13-amino-acid linear sequence to a 7-residue cyclic framework. This conformational restriction preserves the essential His-D-Phe-Arg-Trp motif while dramatically reducing molecular weight and enhancing metabolic stability.
The critical distinction of MT-II lies in its non-selective receptor engagement. Functional cAMP accumulation assays confirm full agonist activity at MC1R, MC3R, MC4R, and MC5R, with EC50 values in the sub-nanomolar to low nanomolar range across all four subtypes. MT-II exhibits approximately 1,000-fold selectivity over MC2R—a safety-relevant characteristic given MC2R’s exclusive role in adrenal steroidogenesis—but shows minimal differentiation among the remaining four subtypes. This pan-receptor agonism makes MT-II a valuable pharmacological tool for studying melanocortin system activation broadly, though it complicates the attribution of observed effects to any single receptor subtype.
Structure-activity relationship (SAR) studies have demonstrated that the cyclic lactam scaffold of MT-II serves as a versatile template for developing subtype-selective analogs. Substitution of D-Phe7 with D-Nal(2′)7 converts MT-II into SHU9119, which retains MC1R and MC5R agonism but functions as an MC3R/MC4R antagonist—illustrating how single-residue modifications at the aromatic position can invert functional activity at specific subtypes (Weirath & Haskell-Luevano, 2024).
PT-141 (Bremelanotide): An MC3R/MC4R-Preferring Cyclic Analog
PT-141 (bremelanotide; Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is the C-terminal free acid metabolite of MT-II. Where MT-II terminates as a C-terminal amide (-NH2), PT-141 presents a free carboxylic acid (-OH) at the same position. This seemingly modest structural difference produces a measurable shift in receptor selectivity: PT-141 retains potent agonism at MC3R and MC4R while exhibiting reduced activity at MC1R relative to MT-II.
The pharmacological consequence of this selectivity shift is significant. MC3R and MC4R are predominantly expressed in hypothalamic nuclei, particularly the paraventricular nucleus (PVN), the arcuate nucleus, and the medial preoptic area (mPOA)—regions that serve as integration centers for appetite regulation, energy expenditure, and neuroendocrine function. Functional studies in cell-based systems expressing human MC4R demonstrate that PT-141 produces robust cAMP accumulation and mini-Gs recruitment with EC50 values in the low nanomolar range (Pfaus et al., 2022).
The reduced MC1R engagement of PT-141 relative to MT-II has been confirmed in comparative binding studies and represents a deliberate pharmacological refinement—concentrating melanocortin agonism at central receptor subtypes while attenuating peripheral pigmentary pathway activation.
Comparative Selectivity: Structural Determinants of Receptor Preference
The selectivity differences among MT-I, MT-II, and PT-141 arise from three principal structural variables:
Linear vs. cyclic architecture. MT-I’s linear backbone permits greater conformational flexibility, allowing adaptation to the orthosteric pocket geometry of multiple receptor subtypes but with preferential fit at MC1R. MT-II and PT-141’s cyclic constraints pre-organize the pharmacophore in a conformation favoring broad MCR engagement.
C-terminal functional group. The amide-to-acid conversion from MT-II to PT-141 alters charge distribution and hydrogen bonding capacity at the C-terminus, modifying interactions with receptor residues lining the intracellular face of the orthosteric pocket. Cryo-EM data from Feng et al. (2023) show that the C-terminal region of melanocortin peptides contacts subtype-specific complementary binding grooves—particularly at MC3R, where γ-MSH’s C-terminus occupies a receptor-specific cleft.
Peptide length and contact surface. MT-I’s 13-residue linear sequence provides additional receptor contacts outside the core pharmacophore, contributing to its enhanced MC1R affinity. The minimal 7-residue cyclic scaffold of MT-II and PT-141 sacrifices these peripheral contacts in favor of metabolic stability and CNS penetration.
Recent work on recommended tool compounds for melanocortin receptor research has systematically characterized these selectivity relationships, establishing NDP-MSH (MT-I), MT-II, and SHU9119 as essential reference ligands for validating cell lines, interpreting cryo-EM structures, and conducting high-throughput screening campaigns (Weirath & Haskell-Luevano, 2024).
These research compounds are sold exclusively for laboratory investigation. They are not intended for human consumption, therapeutic use, or any application outside controlled research settings.
Functional Assay Considerations for Selectivity Profiling
Accurate characterization of melanocortin ligand selectivity requires careful assay design. The constitutive activity exhibited by all five MCR subtypes—now structurally explained by their ability to adopt active-state conformations in the absence of ligand (Feng et al., 2025)—means that standard cAMP accumulation assays must account for elevated basal signaling. Additionally, the discovery that MC4R signals through both Gs and Gq/11α pathways raises the possibility that selectivity profiles may differ depending on which downstream pathway is measured.
Cell-based functional assays using HEK-293 or CHO cells stably expressing individual MCR subtypes remain the gold standard for selectivity determination. Competitive radioligand binding with [125I]-NDP-MSH, cAMP accumulation (AlphaScreen or HTRF formats), and newer NanoBiT-based mini-Gs recruitment assays each capture different aspects of ligand-receptor engagement. For MC4R-targeted compounds specifically, the systematic meta-analysis by Barbosa et al. (2023) provides clinical benchmarking data from setmelanotide studies that contextualize in vitro selectivity findings.
What are the five melanocortin receptor subtypes and where are they expressed?
The melanocortin receptor family consists of MC1R (melanocytes, leukocytes), MC2R (adrenal cortex), MC3R (hypothalamus, limbic system), MC4R (hypothalamus, brainstem), and MC5R (exocrine glands, skeletal muscle, adipose tissue). All five are G protein-coupled receptors that primarily signal through Gs-mediated cAMP production, though MC4R additionally engages Gq/11α signaling.
How does Melanotan I differ structurally from native α-MSH?
Melanotan I ([Nle4,D-Phe7]α-MSH) differs from endogenous α-MSH at two positions: norleucine at position 4 replaces methionine (preventing oxidative degradation), and D-phenylalanine at position 7 replaces L-phenylalanine (enhancing binding affinity and enzymatic stability). These modifications improve MC1R binding affinity by approximately 3-fold while dramatically increasing metabolic half-life.
Why is Melanotan II considered a non-selective melanocortin agonist?
MT-II demonstrates full agonist activity with sub-nanomolar to low nanomolar EC50 values at MC1R, MC3R, MC4R, and MC5R simultaneously. Its cyclic lactam structure constrains the His-D-Phe-Arg-Trp pharmacophore in a conformation that engages the conserved orthosteric pocket across all four responsive subtypes with minimal selectivity differentiation.
What structural modification distinguishes PT-141 from Melanotan II?
PT-141 is the C-terminal free acid (-OH) form of MT-II, which terminates as a C-terminal amide (-NH2). This single functional group change alters the charge distribution and hydrogen bonding interactions at the receptor interface, reducing MC1R engagement while preserving potent MC3R and MC4R agonism.
What is the His-Phe-Arg-Trp pharmacophore and why is it important?
The His-Phe-Arg-Trp (HFRW) tetrapeptide sequence is the minimal motif required for melanocortin receptor activation. Cryo-EM structures confirm that this motif makes extensive contacts within the orthosteric pocket of all responsive MCR subtypes. Modifications to the Phe position (D-Phe, D-Nal) are the primary means by which medicinal chemists modulate subtype selectivity and functional activity (agonism vs. antagonism).
How do cryo-EM structures inform melanocortin ligand design?
Recent cryo-EM structures of all five MCR subtypes—both ligand-bound and unliganded—have revealed subtype-specific features of the orthosteric pocket. For example, MC3R possesses a unique complementary binding groove for the C-terminus of γ-MSH that does not exist in MC4R or MC5R. These structural differences provide rational design templates for developing next-generation subtype-selective agonists and antagonists.
Can melanocortin receptor selectivity be measured using a single assay format?
No single assay captures the full selectivity profile of a melanocortin ligand. Because MCR subtypes exhibit constitutive activity and signal through multiple G protein pathways (Gs, Gq), comprehensive profiling requires competitive binding assays, cAMP accumulation assays, and ideally β-arrestin or mini-G protein recruitment assays across all five subtypes. Ligands may show different selectivity ratios depending on which pathway is measured, a phenomenon termed “biased agonism.”
Related Research Peptides
Researchers investigating melanocortin signaling and neuropeptide receptor pharmacology may also find relevant tools in related peptide families, including Kisspeptin-10 (hypothalamic neuropeptide signaling) and Oxytocin (neuroendocrine GPCR research).
References
Yang Y. Structure, function and regulation of the melanocortin receptors. Eur J Pharmacol. 2011;660(1):125-130. doi:10.1016/j.ejphar.2010.12.020. PubMed
Ji LQ, Hong Y, Tao YX. Melanocortin-5 receptor: pharmacology and its regulation of energy metabolism. Int J Mol Sci. 2022;23(15):8727. doi:10.3390/ijms23158727. PubMed
Israeli H, Degtjarik O, Fierro F, et al. Structure reveals the activation mechanism of the MC4 receptor to initiate satiation signaling. Science. 2021;372(6544):808-814. doi:10.1126/science.abf7958. PubMed
Feng W, Zhou Q, Chen X, et al. Structural insights into ligand recognition and subtype selectivity of the human melanocortin-3 and melanocortin-5 receptors. Cell Discov. 2023;9(1):81. doi:10.1038/s41421-023-00586-4. PubMed
Feng W, Zhou Q, Zheng C, Yang D, Wang MW. Structural basis for the constitutive activity of the melanocortin receptor family. Structure. 2025;33(6):1074-1087.e5. doi:10.1016/j.str.2025.03.004. PubMed
Mun Y, Kim W, Shin D. Melanocortin 1 receptor (MC1R): pharmacological and therapeutic aspects. Int J Mol Sci. 2023;24(15):12152. doi:10.3390/ijms241512152. PubMed
Böhm M, Robert C, Malhotra S, Clément K, Farooqi S. An overview of benefits and risks of chronic melanocortin-1 receptor activation. J Eur Acad Dermatol Venereol. 2025;39:39-51. doi:10.1111/jdv.20269. PubMed
Fontaine T, Busch A, Laeremans T, et al. Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist. Nat Commun. 2024;15(1):7029. doi:10.1038/s41467-024-50827-7. PubMed
Sridhar GR, Gumpeny L. Melanocortin 4 receptor mutation in obesity. World J Exp Med. 2024;14(4):99239. doi:10.5493/wjem.v14.i4.99239. PubMed
Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(3):281-289. doi:10.1017/S109285292100002X. PubMed
Barbosa BF, de Moraes FCA, Barbosa CB, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis. J Pers Med. 2023;13(10):1460. doi:10.3390/jpm13101460. PubMed
Weirath NA, Haskell-Luevano C. Recommended tool compounds for the melanocortin receptor (MCR) G protein-coupled receptors (GPCRs). ACS Pharmacol Transl Sci. 2024. doi:10.1021/acsptsci.4c00129. ACS
The oxytocin peptide is famous as the love hormone, but its real power is in building trust by turning down the volume on your brains fear signals, making it easier to form genuine connections.
Discover how the powerful CJC‑1295 stack, especially when used as an ipamorelin combo, is transforming peptide research with unrivaled support for growth hormone release. Dive in to learn why this dynamic duo is catching the attention of scientists focused on metabolic health, anti-aging, and peak performance.
If you’re curious about buying peptides without a prescription, you’re not alone. The peptide market has exploded in recent years, and understanding what’s legal, what’s safe, and what’s actually available over the counter can be confusing. Here’s the straight answer: Some peptides are available over the counter, but they’re limited to specific types. According to …
Discover how DSIP peptide, a remarkable sleep peptide, is capturing scientific attention for its ability to boost deep sleep, support healthy sleep cycles, and open new doors in sleep research and wellness. Dive in to learn why DSIP peptide may be the breakthrough you’ve been waiting for!
Melanocortin Receptor Subtypes: Selectivity Profiles of Melanotan I, Melanotan II, and PT-141
The following article is intended strictly for educational and research reference purposes. All compounds discussed are for laboratory research use only and are not intended for human or animal consumption.
Introduction: The Melanocortin Receptor Family and Synthetic Peptide Ligands
The melanocortin receptor (MCR) system comprises five G protein-coupled receptor subtypes—MC1R through MC5R—each encoded by distinct genes and expressed across divergent tissue compartments. These receptors are activated by endogenous peptides derived from proopiomelanocortin (POMC), including α-melanocyte-stimulating hormone (α-MSH), β-MSH, γ-MSH, and adrenocorticotropic hormone (ACTH). Despite sharing a conserved His-Phe-Arg-Trp pharmacophore essential for receptor activation, the five subtypes mediate remarkably different physiological processes: MC1R governs melanogenesis in melanocytes, MC2R mediates adrenal steroidogenesis, MC3R and MC4R regulate energy homeostasis and neuroendocrine signaling in the central nervous system, and MC5R modulates exocrine gland function and lipid metabolism in skeletal muscle and adipose tissue (Yang, 2011; Ji et al., 2022).
The relatively low sequence homology (40–60%) among the five receptor subtypes has made the development of subtype-selective ligands a persistent challenge in melanocortin pharmacology. Three synthetic α-MSH analogs—Melanotan I (MT-I, also known as afamelanotide), Melanotan II (MT-II), and PT-141 (bremelanotide)—represent three distinct structural approaches to engaging this receptor family. Their divergent selectivity profiles offer valuable pharmacological tools for dissecting melanocortin signaling in cell-based and in vivo research models.
Receptor Subtype Distribution and Signaling Architecture
All five melanocortin receptors couple primarily to the stimulatory G protein Gs, activating adenylyl cyclase and elevating intracellular cyclic adenosine monophosphate (cAMP). However, recent structural and pharmacological studies have revealed significant complexity beyond this canonical pathway. MC4R, for example, can additionally signal through Gq/11α, and loss of this secondary signaling pathway—even with intact Gs/cAMP coupling—has been shown to produce hyperphagia and obesity in murine models (Sridhar & Gumpeny, 2024).
Landmark cryo-electron microscopy (cryo-EM) studies have now resolved the structures of all five melanocortin receptors. In 2021, Israeli et al. published the first cryo-EM structure of the MC4R–Gs signaling complex bound to setmelanotide at 2.9 Å resolution, revealing a calcium-dependent molecular switch critical for agonist efficacy (Israeli et al., 2021). In 2023, Feng et al. resolved the structures of γ-MSH-bound MC3R–Gs and α-MSH-bound MC5R–Gs complexes, demonstrating that the melanocortin pharmacophore adopts a characteristic “U-shape” conformation within a wide-open orthosteric pocket (Feng et al., 2023). Most recently, Feng et al. (2025) determined unliganded cryo-EM structures of all five MCR–Gs complexes at resolutions between 2.75 and 3.12 Å, providing the structural basis for the constitutive activity that distinguishes this receptor family from most other GPCRs.
These structural advances are complemented by the identification of MC4R-specific orthosteric nanobody agonists that achieve selective receptor activation through binding modalities distinct from peptide ligands (Fontaine et al., 2024).
All compounds referenced herein are intended solely for in vitro and preclinical research applications. These materials are not approved for human or animal use.
Melanotan I: A Linear α-MSH Analog with MC1R Preference
Melanotan I (afamelanotide; [Nle4,D-Phe7]α-MSH) is a 13-amino-acid linear peptide differing from endogenous α-MSH by only two residues: norleucine replaces methionine at position 4, preventing oxidative degradation, and D-phenylalanine replaces L-phenylalanine at position 7, conferring enhanced receptor binding affinity and enzymatic resistance (Mun et al., 2023). The resulting compound, also designated NDP-MSH or NDP-α-MSH, demonstrates dramatically improved binding parameters across all non-MC2R subtypes compared to native α-MSH.
Competitive binding assays have established Ki values for NDP-MSH of approximately 0.085 nM at MC1R, 0.4 nM at MC3R, 3.8 nM at MC4R, and 5.1 nM at MC5R—representing 3- to 1,400-fold improvements over the parent α-MSH peptide at various subtypes. While MT-I retains measurable activity at MC3R, MC4R, and MC5R, its highest affinity is at MC1R, where it functions as a potent full agonist stimulating eumelanin biosynthesis through the tyrosinase pathway. The MC1R selectivity ratio (MC1R vs. MC4R) of approximately 45-fold provides meaningful, though not absolute, preferential engagement of the pigmentation pathway (Mun et al., 2023; Böhm et al., 2025).
Melanotan II: A Cyclic Non-Selective Pan-MCR Agonist
Melanotan II (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) represents a fundamentally different structural approach. Cyclization of the core pharmacophore through a lactam bridge between Asp5 and Lys10 constrains the peptide backbone, reducing the 13-amino-acid linear sequence to a 7-residue cyclic framework. This conformational restriction preserves the essential His-D-Phe-Arg-Trp motif while dramatically reducing molecular weight and enhancing metabolic stability.
The critical distinction of MT-II lies in its non-selective receptor engagement. Functional cAMP accumulation assays confirm full agonist activity at MC1R, MC3R, MC4R, and MC5R, with EC50 values in the sub-nanomolar to low nanomolar range across all four subtypes. MT-II exhibits approximately 1,000-fold selectivity over MC2R—a safety-relevant characteristic given MC2R’s exclusive role in adrenal steroidogenesis—but shows minimal differentiation among the remaining four subtypes. This pan-receptor agonism makes MT-II a valuable pharmacological tool for studying melanocortin system activation broadly, though it complicates the attribution of observed effects to any single receptor subtype.
Structure-activity relationship (SAR) studies have demonstrated that the cyclic lactam scaffold of MT-II serves as a versatile template for developing subtype-selective analogs. Substitution of D-Phe7 with D-Nal(2′)7 converts MT-II into SHU9119, which retains MC1R and MC5R agonism but functions as an MC3R/MC4R antagonist—illustrating how single-residue modifications at the aromatic position can invert functional activity at specific subtypes (Weirath & Haskell-Luevano, 2024).
PT-141 (Bremelanotide): An MC3R/MC4R-Preferring Cyclic Analog
PT-141 (bremelanotide; Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is the C-terminal free acid metabolite of MT-II. Where MT-II terminates as a C-terminal amide (-NH2), PT-141 presents a free carboxylic acid (-OH) at the same position. This seemingly modest structural difference produces a measurable shift in receptor selectivity: PT-141 retains potent agonism at MC3R and MC4R while exhibiting reduced activity at MC1R relative to MT-II.
The pharmacological consequence of this selectivity shift is significant. MC3R and MC4R are predominantly expressed in hypothalamic nuclei, particularly the paraventricular nucleus (PVN), the arcuate nucleus, and the medial preoptic area (mPOA)—regions that serve as integration centers for appetite regulation, energy expenditure, and neuroendocrine function. Functional studies in cell-based systems expressing human MC4R demonstrate that PT-141 produces robust cAMP accumulation and mini-Gs recruitment with EC50 values in the low nanomolar range (Pfaus et al., 2022).
The reduced MC1R engagement of PT-141 relative to MT-II has been confirmed in comparative binding studies and represents a deliberate pharmacological refinement—concentrating melanocortin agonism at central receptor subtypes while attenuating peripheral pigmentary pathway activation.
Comparative Selectivity: Structural Determinants of Receptor Preference
The selectivity differences among MT-I, MT-II, and PT-141 arise from three principal structural variables:
Linear vs. cyclic architecture. MT-I’s linear backbone permits greater conformational flexibility, allowing adaptation to the orthosteric pocket geometry of multiple receptor subtypes but with preferential fit at MC1R. MT-II and PT-141’s cyclic constraints pre-organize the pharmacophore in a conformation favoring broad MCR engagement.
C-terminal functional group. The amide-to-acid conversion from MT-II to PT-141 alters charge distribution and hydrogen bonding capacity at the C-terminus, modifying interactions with receptor residues lining the intracellular face of the orthosteric pocket. Cryo-EM data from Feng et al. (2023) show that the C-terminal region of melanocortin peptides contacts subtype-specific complementary binding grooves—particularly at MC3R, where γ-MSH’s C-terminus occupies a receptor-specific cleft.
Peptide length and contact surface. MT-I’s 13-residue linear sequence provides additional receptor contacts outside the core pharmacophore, contributing to its enhanced MC1R affinity. The minimal 7-residue cyclic scaffold of MT-II and PT-141 sacrifices these peripheral contacts in favor of metabolic stability and CNS penetration.
Recent work on recommended tool compounds for melanocortin receptor research has systematically characterized these selectivity relationships, establishing NDP-MSH (MT-I), MT-II, and SHU9119 as essential reference ligands for validating cell lines, interpreting cryo-EM structures, and conducting high-throughput screening campaigns (Weirath & Haskell-Luevano, 2024).
These research compounds are sold exclusively for laboratory investigation. They are not intended for human consumption, therapeutic use, or any application outside controlled research settings.
Functional Assay Considerations for Selectivity Profiling
Accurate characterization of melanocortin ligand selectivity requires careful assay design. The constitutive activity exhibited by all five MCR subtypes—now structurally explained by their ability to adopt active-state conformations in the absence of ligand (Feng et al., 2025)—means that standard cAMP accumulation assays must account for elevated basal signaling. Additionally, the discovery that MC4R signals through both Gs and Gq/11α pathways raises the possibility that selectivity profiles may differ depending on which downstream pathway is measured.
Cell-based functional assays using HEK-293 or CHO cells stably expressing individual MCR subtypes remain the gold standard for selectivity determination. Competitive radioligand binding with [125I]-NDP-MSH, cAMP accumulation (AlphaScreen or HTRF formats), and newer NanoBiT-based mini-Gs recruitment assays each capture different aspects of ligand-receptor engagement. For MC4R-targeted compounds specifically, the systematic meta-analysis by Barbosa et al. (2023) provides clinical benchmarking data from setmelanotide studies that contextualize in vitro selectivity findings.
Research-grade peptides with verified purity are essential for reproducible selectivity profiling. Oath Research provides third-party certificates of analysis for all melanocortin peptides, including Melanotan I, Melanotan II, and PT-141.
Frequently Asked Questions
What are the five melanocortin receptor subtypes and where are they expressed?
The melanocortin receptor family consists of MC1R (melanocytes, leukocytes), MC2R (adrenal cortex), MC3R (hypothalamus, limbic system), MC4R (hypothalamus, brainstem), and MC5R (exocrine glands, skeletal muscle, adipose tissue). All five are G protein-coupled receptors that primarily signal through Gs-mediated cAMP production, though MC4R additionally engages Gq/11α signaling.
How does Melanotan I differ structurally from native α-MSH?
Melanotan I ([Nle4,D-Phe7]α-MSH) differs from endogenous α-MSH at two positions: norleucine at position 4 replaces methionine (preventing oxidative degradation), and D-phenylalanine at position 7 replaces L-phenylalanine (enhancing binding affinity and enzymatic stability). These modifications improve MC1R binding affinity by approximately 3-fold while dramatically increasing metabolic half-life.
Why is Melanotan II considered a non-selective melanocortin agonist?
MT-II demonstrates full agonist activity with sub-nanomolar to low nanomolar EC50 values at MC1R, MC3R, MC4R, and MC5R simultaneously. Its cyclic lactam structure constrains the His-D-Phe-Arg-Trp pharmacophore in a conformation that engages the conserved orthosteric pocket across all four responsive subtypes with minimal selectivity differentiation.
What structural modification distinguishes PT-141 from Melanotan II?
PT-141 is the C-terminal free acid (-OH) form of MT-II, which terminates as a C-terminal amide (-NH2). This single functional group change alters the charge distribution and hydrogen bonding interactions at the receptor interface, reducing MC1R engagement while preserving potent MC3R and MC4R agonism.
What is the His-Phe-Arg-Trp pharmacophore and why is it important?
The His-Phe-Arg-Trp (HFRW) tetrapeptide sequence is the minimal motif required for melanocortin receptor activation. Cryo-EM structures confirm that this motif makes extensive contacts within the orthosteric pocket of all responsive MCR subtypes. Modifications to the Phe position (D-Phe, D-Nal) are the primary means by which medicinal chemists modulate subtype selectivity and functional activity (agonism vs. antagonism).
How do cryo-EM structures inform melanocortin ligand design?
Recent cryo-EM structures of all five MCR subtypes—both ligand-bound and unliganded—have revealed subtype-specific features of the orthosteric pocket. For example, MC3R possesses a unique complementary binding groove for the C-terminus of γ-MSH that does not exist in MC4R or MC5R. These structural differences provide rational design templates for developing next-generation subtype-selective agonists and antagonists.
Can melanocortin receptor selectivity be measured using a single assay format?
No single assay captures the full selectivity profile of a melanocortin ligand. Because MCR subtypes exhibit constitutive activity and signal through multiple G protein pathways (Gs, Gq), comprehensive profiling requires competitive binding assays, cAMP accumulation assays, and ideally β-arrestin or mini-G protein recruitment assays across all five subtypes. Ligands may show different selectivity ratios depending on which pathway is measured, a phenomenon termed “biased agonism.”
Related Research Peptides
Researchers investigating melanocortin signaling and neuropeptide receptor pharmacology may also find relevant tools in related peptide families, including Kisspeptin-10 (hypothalamic neuropeptide signaling) and Oxytocin (neuroendocrine GPCR research).
References
2 Day FAST Shipping
99%+ Purity Tests
Ships from Gilbert Arizona
USA Lab Tested
Free bacteriostatic water with every order.
Related Posts
Oxytocin Peptide: How Does Oxytocin Peptide Build Trust?
The oxytocin peptide is famous as the love hormone, but its real power is in building trust by turning down the volume on your brains fear signals, making it easier to form genuine connections.
CJC‑1295 Stack: Notable Ipamorelin Combo for Top GH Release
Discover how the powerful CJC‑1295 stack, especially when used as an ipamorelin combo, is transforming peptide research with unrivaled support for growth hormone release. Dive in to learn why this dynamic duo is catching the attention of scientists focused on metabolic health, anti-aging, and peak performance.
Can I Buy Peptides Over the Counter?
If you’re curious about buying peptides without a prescription, you’re not alone. The peptide market has exploded in recent years, and understanding what’s legal, what’s safe, and what’s actually available over the counter can be confusing. Here’s the straight answer: Some peptides are available over the counter, but they’re limited to specific types. According to …
DSIP Peptide: Stunning Sleep Peptide Benefits You Need to Know
Discover how DSIP peptide, a remarkable sleep peptide, is capturing scientific attention for its ability to boost deep sleep, support healthy sleep cycles, and open new doors in sleep research and wellness. Dive in to learn why DSIP peptide may be the breakthrough you’ve been waiting for!